Influenza (flu) is a contagious respiratory disease caused by influenza viruses that infect the
respiratory tract (nose, throat, and lungs) in humans. The symptoms and complications of
flu are more severe than common cold. The symptoms associated with influenza may
include fever, headache, malaise, cough, sore throat, nasal congestion, and body aches.
Influenza vaccine can prevent illness and death caused by the influenza virus. Influenza
vaccine can be administrated to both young and old patients. According to the Centers for
Disease Control and Prevention in 2017, 67.2% of all the geriatric population within the U.S.
suffered from influenza in 2016. Moreover, it was estimated that the disease caused 4,605
deaths in 2014. Such trends in the prevalence of influenza are the major driver for the
market growth during the forecast period. Moreover, the immune-compromised growing
geriatric population, increasing per capita healthcare expenditure and rising awareness of
the disease will fuel the market growth. According to the National Institutes of Health, the
people who age 80 or more are expected to grow from 126.5 million in 2015 to 446.6
million by 2050. However, stringent regulatory framework along with the low accessibility of
the product in the developing countries may restrain the market growth.
The Global Influenza Vaccination Market is expected to grow at an approximate CAGR of
8.2% during the forecast period.
Segmentation
The Global Influenza Vaccination Market is segmented on the basis of type of influenza,
manufacturing technology, vaccines, and others.
On the basis of the type of influenza, the market is segmented into seasonal, pandemic,
zoonotic, and others.
On the basis of the manufacturing technology, the market is segmented into egg based, cell
culture based, recombination based technology, and others.
On the basis of the vaccines, the market is segmented into fluzone, flumist, fluvax, fluvirin,
and others.
On the basis of the end users, the market is segmented into hospital & clinics, research
organization, academic institutes, and others.
Key players for global influenza vaccination market
Global Influenza Vaccination Market are Abbott (U.S.), AstraZeneca (Europe), BioCryst
Pharmaceuticals, Inc. (U.S.), Novartis AG (Europe), DAIICHI SANKYO COMPANY, LIMITED.
(Asia Pacific), GlaxoSmithKline plc. (Europe). Hualan Biological Engineering Inc (Asia
Pacific), Mitsubishi Tanabe Pharma Corporation (Asia Pacific), F. Hoffmann-La Roche Ltd
(Europe), Sanofi (Europe), and others.
Get Sample Copy at https://www.marketresearchfuture.com/sample_request/1621 .
Regional Analysis
The Americas dominate the Global Influenza Vaccination Market owing to the increasing
prevalence of influenza and the high per capita healthcare expenditure. Moreover, the
presence of the developed economies like the U.S. and Canada within the region boosts the
growth of the market. Additionally, growing geriatric population within the regional
boundaries of the Americas fuels the market growth. According to the National Institutes of
Health, the America’s geriatric population is expected to reach 88 million by 2050.
Europe is the second largest market for influenza vaccination, which is followed by Asia
Pacific. Availability of funds for research, a well-developed healthcare infrastructure, and a
huge patient population drives the market growth within the region. Moreover, rising
healthcare expenditure along with the government support for research & development